SS-31 research record explained: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced Cardiomyoblast H9C2 Cell Senescence.

Quick answer

For “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” in laboratory studies on heart muscle cells, SS-31 reduced markers of cellular senescence induced by radiation and by the chemotherapy drug doxorubicin.¹

These are cell-culture studies and do not represent human outcomes.¹ For Filipino readers, “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…” is best read by matching every conclusion to the exact study, population, outcome, and product identity. The Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.²

What did this SS-31 record actually examine?

For “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” start with the recorded result, not the marketing version. In laboratory studies on heart muscle cells, SS-31 reduced markers of cellular senescence induced by radiation and by the chemotherapy drug doxorubicin.¹

Within “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” One study showed SS-31 reduced senescence-associated beta-galactosidase staining from 67% to 38% in irradiated H9C2 cells. Another showed SS-31 partially attenuated doxorubicin-induced SA-β-gal staining from 51.4% to 35.8%.¹ These are cell-culture studies and do not represent human outcomes.¹

For “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” that boundary keeps one result from becoming a universal promise. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

For “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” the clearest route is to separate the result from its interpretation. WHO states that some falsified medical products can closely resemble genuine products and may require quality-control analysis.³

Within “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” WHO guidance on suspected falsified medical products and regulatory laboratory testing.³ Appearance alone cannot authenticate a product or establish a research outcome.³

In “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” the careful reading is narrower than a social-media headline. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

The plain-language rule for “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…” is simple: identify what was measured before asking what it might mean elsewhere. A precise answer can still be interesting; it simply keeps the reader oriented.

Readers researching SS-31 can view its live catalog details below. The listing identifies the catalog item and is separate from the evidence discussed here.

What was the main finding?

For “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” one precise finding is more useful than a broad slogan. SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.⁴

Within “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” The FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder. A laboratory study notes SS-31's known property of mitochondrial inner membrane binding.⁴ This is a description of its mechanism of action from regulatory and laboratory sources.⁴

That distinction gives “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…” a useful answer without making it sound larger than the evidence. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

For “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” the study becomes easier to read when its boundaries remain visible. A study record is most useful when its reported result remains attached to the population, design, source identifier, and exact product identity.⁵

Within “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” Editorial synthesis of the canonical research records and Philippine verification sources.⁵ This synthesis is educational and is not personal medical advice or a product recommendation.⁵

Keeping that boundary visible makes “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…” clearer for a general reader. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

A useful magazine explanation of “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…” should make the main point easy to find. It should also keep the study boundary close enough that readers do not need to hunt for it.

Which study details change the interpretation?

For “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” a useful summary begins with the outcome the researchers actually recorded. The MMPOWER-3 phase 3 trial in 218 adults with primary mitochondrial myopathy did not meet its primary endpoints for improving the six-minute walk distance or total fatigue score after 24 weeks.⁶

Within “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” The MMPOWER-3 randomized, placebo-controlled trial reported that the study did not meet its primary efficacy endpoints for change in 6MWT or PMMSA total fatigue score at week 24.⁶ This was the overall result for a genetically diverse population.⁶

This is the point where “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…” changes from a claim into an evidence question. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

This reading of “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…” avoids two common errors. It does not dismiss a narrow finding, and it does not stretch that finding beyond the question researchers asked.

What should not be borrowed from the result?

For “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” start with the recorded result, not the marketing version. In a 12-week randomized trial of 12 males with Barth syndrome, the primary endpoints included the distance walked in six minutes and a measure of muscle strength.⁷

Within “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” The FDA snapshot summary describes the randomized portion of the SPIBA-201 trial, which evaluated efficacy in 12 patients aged ≥12 years with genetically confirmed Barth syndrome.⁷ The snapshot reports the trial design and endpoints but does not provide the numerical results for the primary endpoints.⁷

For “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” that boundary keeps one result from becoming a universal promise. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

How does the wider evidence sharpen the picture?

For “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” one precise finding is more useful than a broad slogan. In a long-term open-label extension of the TAZPOWER trial, people with Barth syndrome who continued elamipretide showed a cumulative improvement of 96.1 meters on the six-minute walk test over 168 weeks.⁸

Within “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” The 168-week open-label extension of the TAZPOWER trial reported significant improvements from baseline on the 6MWT at all time points, with a cumulative 96.1 m improvement at week 168 (P = .003). Ten patients entered the extension, and eight completed it.⁸ This was an open-label study with a small number of participants, and all knew they were receiving the active drug.⁸

A catalog card does not change the evidence boundary in “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…”.⁵ It helps readers locate a live item while the article keeps scientific and product questions separate.⁵

Readers comparing this topic with MOTS-C can view its live catalog details below. It is a separate catalog reference, not a suggested combination.

What should Filipino readers verify next?

For “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” a useful summary begins with the outcome the researchers actually recorded. The Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.²

Within “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” Official Philippine regulatory verification service.² A portal record applies to the exact product or establishment named in that record.²

Bottom line

For “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” one study showed SS-31 reduced senescence-associated beta-galactosidase staining from 67% to 38% in irradiated H9C2 cells. Another showed SS-31 partially attenuated doxorubicin-induced SA-β-gal staining from 51.4% to 35.8%.¹ These are cell-culture studies and do not represent human outcomes.¹

The Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.² For “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” this check belongs beside the science rather than underneath it.

The practical conclusion for “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…” is informed interest with exact source, context, and product boundaries intact. That makes the article useful without turning it into a sales promise or a personal recommendation.

Frequently asked questions

What is the fastest way to understand SS-31?

In laboratory studies on heart muscle cells, SS-31 reduced markers of cellular senescence induced by radiation and by the chemotherapy drug doxorubicin.¹ For “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” begin there, then keep the study setting and stated limit beside the result instead of jumping to a broader conclusion.

Does one positive finding settle the whole topic?

No. This is a description of its mechanism of action from regulatory and laboratory sources.⁴ In “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” a finding can be useful while remaining narrow, early, or tied to one measured outcome.

Why does the study context matter?

The MMPOWER-3 randomized, placebo-controlled trial reported that the study did not meet its primary efficacy endpoints for change in 6MWT or PMMSA total fatigue score at week 24.⁶ For “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” changing the population, design, formulation, or outcome changes the question being answered.

What should Filipino readers verify?

The Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.² While reading “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” check the exact product and establishment details rather than relying on a familiar molecule name.

Do the SS-31 and MOTS-C cards prove a benefit?

No. In “SS-31: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced…,” they are live catalog references for navigation. They do not turn a study result into a product claim, prove equivalence, or suggest using the items together.⁵

Sources

Footnotes

1. Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence.; Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced Cardiomyoblast H9C2 Cell Senescence.. One study showed SS-31 reduced senescence-associated beta-galactosidase staining from 67% to 38% in irradiated H9C2 cells. Another showed SS-31 partially attenuated doxorubicin-induced SA-β-gal staining from 51.4% to 35.8%. These are cell-culture studies and do not represent human outcomes. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

2. Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Official Philippine regulatory verification service. A portal record applies to the exact product or establishment named in that record. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

3. WHO laboratory analysis of suspected falsified medical products; WHO laboratory testing for health-product regulation. WHO guidance on suspected falsified medical products and regulatory laboratory testing. Appearance alone cannot authenticate a product or establish a research outcome. ↩ ↩² ↩³

4. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE); Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.. The FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder. A laboratory study notes SS-31's known property of mitochondrial inner membrane binding. This is a description of its mechanism of action from regulatory and laboratory sources. ↩ ↩² ↩³ ↩⁴

5. Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence.; Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced Cardiomyoblast H9C2 Cell Senescence.; FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE); Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.; Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.; Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Editorial synthesis of the canonical research records and Philippine verification sources. This synthesis is educational and is not personal medical advice or a product recommendation. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

6. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.. The MMPOWER-3 randomized, placebo-controlled trial reported that the study did not meet its primary efficacy endpoints for change in 6MWT or PMMSA total fatigue score at week 24. This was the overall result for a genetically diverse population. ↩ ↩² ↩³ ↩⁴

7. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE). The FDA snapshot summary describes the randomized portion of the SPIBA-201 trial, which evaluated efficacy in 12 patients aged ≥12 years with genetically confirmed Barth syndrome. The snapshot reports the trial design and endpoints but does not provide the numerical results for the primary endpoints. ↩ ↩² ↩³

8. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.. The 168-week open-label extension of the TAZPOWER trial reported significant improvements from baseline on the 6MWT at all time points, with a cumulative 96.1 m improvement at week 168 (P = .003). Ten patients entered the extension, and eight completed it. This was an open-label study with a small number of participants, and all knew they were receiving the active drug. ↩ ↩² ↩³